Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention

被引：0
|
作者：
Itziar Oyagüez
Carmen Suárez
José Luis López-Sendón
José Ramón González-Juanatey
Fernando de Andrés-Nogales
Jorge Suárez
Carlos Polanco
Javier Soto
机构：
[1] Pharmacoeconomics and Outcomes Research Iberia (PORIB),Internal Medicine Department
[2] Hospital La Princesa,Cardiology Department
[3] Hospital Universitario La Paz,Cardiology Department
[4] IdiPaz,undefined
[5] CIBER-CV,undefined
[6] Complejo Hospitalario Universitario de Compostela,undefined
[7] Bristol-Myers Squibb,undefined
[8] Pfizer,undefined
来源：
PharmacoEconomics - Open | 2020年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：485 / 497
页数：12
相关论文
共 50 条
  • [11] Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation
    Xiong, Qinmei
    Lau, Yee C.
    Lip, Gregory Y. H.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2015, 4 (04) : 367 - 376
  • [12] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 39 (02) : 149 - 154
  • [13] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    Journal of Thrombosis and Thrombolysis, 2015, 39 : 149 - 154
  • [14] Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
    Lee, Soyon
    Mullin, Rachel
    Blazawski, Jon
    Coleman, Craig I.
    PLOS ONE, 2012, 7 (10):
  • [15] COST-EFFECTIVENESS OF APIXABAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION: AN KAZAKHSTAN PERSPECTIVE
    Kostyuk, A.
    Almadiyeva, A.
    Nurgozhin, T.
    VALUE IN HEALTH, 2017, 20 (09) : A615 - A615
  • [16] COST-EFFECTIVENESS OF APIXABAN COMPARED TO ASPIRIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
    Lee, Soyon
    Anglade, Moise
    Hagstrom, Kelly
    Meng, Joy
    Kluger, Jeffrey
    Coleman, Craig
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E596 - E596
  • [17] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS RIVAROXABAN FOR PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN SPAIN
    Canal Fontcuberta, G.
    Escolar Albaladejo, G.
    Betegon Nicolas, L.
    de Salas-Cansado, M.
    Rubio-Rodriguez, D.
    Rubio-Terres, G.
    VALUE IN HEALTH, 2013, 16 (07) : A523 - A523
  • [18] COST-EFFECTIVENESS OF APIXABAN VERSUS OTHER NEW ORAL ANTICOAGULANTS FOR THE PREVENTION OF STROKE: AN ANALYSIS OF PATIENTS WITH ATRIAL FIBRILLATION IN GREECE
    Athanasakis, K.
    Arzoumanidou, D.
    Karampli, E.
    Armelidou, E.
    Giovas, P.
    Petrikkou, E.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2013, 16 (07) : A525 - A525
  • [19] Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
    Lip, Gregory Y. H.
    Kongnakorn, Thitima
    Phatak, Hemant
    Kuznik, Andreas
    Lanitiss, Tereza
    Liu, Larry Z.
    Iloeje, Uchenna
    Hernandez, Luis
    Dorian, Paul
    CLINICAL THERAPEUTICS, 2014, 36 (02) : 192 - 210
  • [20] Cost-effectiveness Analysis Comparing Apixaban and Acenocoumarol in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation in Spain
    Baron Esquivias, Gonzalo
    Escolar Albaladejo, Gines
    Luis Zamorano, Jose
    Betegon Nicolas, Lourdes
    Canal Fontcuberta, Cristina
    de Salas-Cansado, Marina
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    REVISTA ESPANOLA DE CARDIOLOGIA, 2015, 68 (08): : 680 - 690
12345